Indication
Pulmonary Tuberculosis
5 clinical trials
15 products
Clinical trial
Economic Evaluation of New MDR TB Regimens (PRACTECAL EE)Status: Completed, Estimated PCD: 2022-08-25
Product
BedaquilineProduct
PretomanidProduct
MoxifloxacinProduct
LinezolidProduct
ClofazimineProduct
Standard DrugsClinical trial
Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical TrialStatus: Completed, Estimated PCD: 2023-06-01
Product
DelamanidProduct
LevofloxacinProduct
PyrazinamideProduct
Control arm MDR-TB regimenClinical trial
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase IIB, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Sutezolid in Combination With Bedaquiline, Delamanid and Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary TuberculosisStatus: Completed, Estimated PCD: 2022-09-30
Product
SutezolidProduct
MidazolamClinical trial
A Multiple Arm, Multiple Stage (MAMS), Phase 2B/C, Open Label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including an Increased Dose of Rifampicin, an Optimized Dose of Pyrazinamide, Moxifloxacin and BTZ-043, in Adults With Newly Diagnosed, Drug Sensitive, Smear-positive Pulmonary Tuberculosis.Status: Recruiting, Estimated PCD: 2025-02-23
Product
BTZ-043Product
RifampicinProduct
Isoniazid